Cagrilintide 5mg

Cagrilintide is rapidly emerging as a potent and promising compound in the field of peptide-based therapeutics for appetite regulation and weight loss. Originally developed as part of a synergistic combination therapy with semaglutide (by Novo Nordisk), this long-acting amylin analog is now being studied independently for its powerful effects on satiety and caloric intake.

Mechanism of Action:
Cagrilintide mimics the natural hormone amylin, which is co-secreted with insulin by pancreatic beta cells. Amylin plays a crucial role in regulating gastric emptying, glucagon secretion, and satiety signaling through the brain’s area postrema and nucleus tractus solitarius. Cagrilintide, as a stable and long-acting analog, binds more effectively to amylin receptors, creating prolonged appetite suppression.

Clinical and Research Results:
Studies have shown that when used on its own—or in combination with GLP-1 receptor agonists like semaglutide—Cagrilintide can lead to significant reductions in body weight, often exceeding those seen with GLP-1s alone. In human trials, weekly administration of Cagrilintide resulted in:

• Up to 10–15% reductions in body weight over 20–26 weeks
• Noticeable decrease in hunger and meal size
• Improved glycemic control in patients with Type 2 diabetes

When paired with semaglutide (as in the co-formulated compound CagriSema), the results have been particularly impressive, showing potential for a multi-pronged attack on obesity through both amylin and GLP-1 pathways.